BridgeBio Pharma Announces Publication of Positive Results from Phase 3 ATTRibute-CM Study of Acoramidis for Patients with Transthyretin Amyloid Cardiomyopathy (ATTR-CM) in the New England Journal of Medicine

January 10, 2024

https://www.globenewswire.com/news-release/2024/01/10/2807550/0/en/BridgeBio-Pharma-Announces-Publication-of-Positive-Results-from-Phase-3-ATTRibute-CM-Study-of-Acoramidis-for-Patients-with-Transthyretin-Amyloid-Cardiomyopathy-ATTR-CM-in-the-New-E.html

– ATTRibute-CM demonstrated a significant treatment effect of acoramidis on the primary endpoint (a hierarchical analysis inclusive of all-cause mortality (ACM) and frequency of cardiovascular-related hospitalization (CVH)), with a Win Ratio of 1.8 (p<0.0001)

Read more at globenewswire.com

Related news for (BBIO)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.